Acutaas Chemicals Limited (NSE: ACUTAAS), a leading global manufacturer of advanced pharmaceutical intermediates and specialty chemicals, today announced financial results for the quarter and half year ended September 30, 2026. The company reported a robust performance with significant growth in revenue and profit.

Financial Highlights

The company’s revenue from operations for Q2 FY27 grew by 42.7% year-on-year to ₹4,369 million. The profit after tax (PAT) for the quarter was ₹1,231 million, up 71.4% YoY. The EBITDA for the quarter came at ₹1,760 million, up 84.6% YoY.

Margin Improvements

The gross margin for the quarter improved to 62.1%, up 637 basis points YoY. The EBITDA margin for the quarter was at 40.3%, compared to 31.1% in Q2 FY26. The PAT margin for the quarter was at 28.2%, up 472 basis points YoY.

Forward Guidance

Commenting on the results, Mr. Naresh Patel, Executive Chairman & Managing Director, said, ‘We delivered strong revenue of ₹4,369 million, representing 42.7% year-on-year growth. Improved revenue visibility and a robust order pipeline gives me confidence to revise our FY27 revenue growth guidance upward from 25% to around 30%. We are also raising our EBITDA margin guidance to the 38-40% range.’

The company’s strategic initiatives, including the inauguration of its South Korea manufacturing facility ahead of schedule, are well-positioned to capitalize on opportunities in the fast-growing semiconductor ecosystem.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Acutaas Chemicals Limited

Acutaas Chemicals Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Acutaas falls 11.4% over three months and has not found a floor yet. Industry-leading margins of 26.4% reflect exceptional pricing power and operational efficiency. Revenue grows at 29.4% and profits at 62.3% CAGR. Both numbers are exceptional. The stock trades at 76% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 29.4%, profits at 62.3%, and the PEG sits at 1.09 — below its growth rate. That combination is rare. Check Fundamentals of Acutaas Chemicals Limited.

Acutaas Chemicals Limited (BSE: 543349, NSE: ACUTAAS), a leading India-based manufacturer of specialty chemicals and pharmaceutical intermediates, announced the inauguration of its step-down subsidiary Indichem Inc.’s semiconductor materials plant at Gongju, South Korea. The plant, inaugurated today, was built in just eleven months and will synthesize chemicals in India and refine them to semiconductor grade in South Korea.

State-of-the-Art Facility

The semiconductor materials plant was inaugurated at a ceremony held today at the facility. The plant, completed within 11 months of its groundbreaking on September 29, 2025, spans 16,513.7 sq. m. across three buildings, including a main production block, combined headquarters/R&D/pilot plant, and warehouse. Additional land is available on-site for future expansion.

Strategic Two-Country Model

A synergistic two-country model has been adopted, where chemicals are synthesized in India and refined to semiconductor grade in South Korea. This model leverages India’s strengths in complex chemical synthesis and South Korea’s expertise in ultra-high-purity refining. This approach aims to create a resilient and geographically diversified supply chain for global chip and display makers.

Speaking on the occasion, Mr. Naresh Patel, Chairman & Managing Director of Acutaas Chemicals Limited, said: “We are thrilled to inaugurate the Gongju plant just eleven months after breaking ground, reflecting the exceptional discipline brought by both partners. By combining India’s core strengths in complex chemical synthesis with Korea’s expertise in ultra-high-purity refining, we have built a synergistic model that neither company could have executed alone. This marks a vital step in scaling our semiconductor materials business into a long-term growth engine for Acutaas.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Acutaas Chemicals Limited

Acutaas Chemicals Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Acutaas holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG reaches 3.16. The stock trades on brand and index weight, not on growth. Industry-leading margins of 26.4% reflect exceptional pricing power and operational efficiency. The stock trades at 83% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 24.3% and profits at 30.2%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Acutaas Chemicals Limited.

Acutaas Chemicals Limited (ACUTAAS) breaks below support, falling -5% today. The stock has breached its 6-month support trendline, signaling a breakdown in the technical structure. Acutaas operates in the specialty chemicals segment of the basic materials sector, and today’s move appears to be company-specific rather than a sector-wide phenomenon.

Technical setup — trendlines & DMA

The 6-month support trendline for Acutaas was at ₹3669.98, and the stock is now trading 14.97% below this level, indicating a breakdown. Resistance is further up at ₹3918.2, which is 22.75% above the current price. The 50-day moving average (DMA) is at ₹3276.9, slightly above the current price, while the 200-DMA is at ₹2331.9, well below. This suggests that while the stock is in a bullish trend in the longer term, it is currently under pressure. The stock is in the upper third of its 52-week range, implying that a significant portion of its yearly gains may already be priced in.

Fundamentals & business context

With a PE ratio of 96.6, Acutaas is trading at a high multiple relative to its profit margin of 26.4% and revenue CAGR of 24.3%. This suggests that the market may be pricing in future growth expectations, potentially stretching the current valuation. Institutional ownership stands at 27.9%, indicating a moderate level of confidence from smart money. There is no NSE catalyst today, and the move is primarily technical.

Algorithmic scorecard

The overall scorecard reflects a balanced view, with strong revenue and profit growth but concerns over valuation and dividend yield. The strongest signals are the excellent revenue and profit CAGRs, indicating robust business performance and consistent growth. The weak signals include the overvalued PEG ratio and negligible dividend yield, which suggest that the stock may be expensive relative to its growth rate and offers little income to shareholders.

Company outlook

Management guided for 25% revenue growth in FY ’27 and expects to maintain EBITDA margins at a similar level. The battery chemical business and four validated CDMO products are expected to contribute meaningfully to revenue. The company plans to complete the second phase of electrolyte additive capex by Q1 FY ’27 and is evaluating land acquisition opportunities for new infrastructure.

Get all details on ACUTAAS — P&L, peers, shareholding and more on TradeAlone.